These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21618474)

  • 1. Evaluation of protein engineering and process optimization approaches to enhance antibody drug manufacturability.
    Conley GP; Viswanathan M; Hou Y; Rank DL; Lindberg AP; Cramer SM; Ladner RC; Nixon AE; Chen J
    Biotechnol Bioeng; 2011 Nov; 108(11):2634-44. PubMed ID: 21618474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using partition designs to enhance purification process understanding.
    Pieracci J; Perry L; Conley L
    Biotechnol Bioeng; 2010 Dec; 107(5):814-24. PubMed ID: 20632374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward aggregation-resistant antibodies by design.
    Lee CC; Perchiacca JM; Tessier PM
    Trends Biotechnol; 2013 Nov; 31(11):612-20. PubMed ID: 23932102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based engineering of a monoclonal antibody for improved solubility.
    Wu SJ; Luo J; O'Neil KT; Kang J; Lacy ER; Canziani G; Baker A; Huang M; Tang QM; Raju TS; Jacobs SA; Teplyakov A; Gilliland GL; Feng Y
    Protein Eng Des Sel; 2010 Aug; 23(8):643-51. PubMed ID: 20543007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody engineering and modification technologies.
    Filpula D
    Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines to cell engineering for monoclonal antibody production.
    Rita Costa A; Elisa Rodrigues M; Henriques M; Azeredo J; Oliveira R
    Eur J Pharm Biopharm; 2010 Feb; 74(2):127-38. PubMed ID: 19853660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of Fc-mediated effector functions of monoclonal antibodies.
    Strohl WR
    Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing stability of antibody via antibody engineering: stability engineering on an anti-hVEGF.
    Wang S; Liu M; Zeng D; Qiu W; Ma P; Yu Y; Chang H; Sun Z
    Proteins; 2014 Oct; 82(10):2620-30. PubMed ID: 24916692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering fully human monoclonal antibodies from murine variable regions.
    Bernett MJ; Karki S; Moore GL; Leung IW; Chen H; Pong E; Nguyen DH; Jacinto J; Zalevsky J; Muchhal US; Desjarlais JR; Lazar GA
    J Mol Biol; 2010 Mar; 396(5):1474-90. PubMed ID: 20045416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational and systematic protein purification process development: the next generation.
    Nfor BK; Verhaert PD; van der Wielen LA; Hubbuch J; Ottens M
    Trends Biotechnol; 2009 Dec; 27(12):673-9. PubMed ID: 19815300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.
    Tanha J; Nguyen TD; Ng A; Ryan S; Ni F; Mackenzie R
    Protein Eng Des Sel; 2006 Nov; 19(11):503-9. PubMed ID: 16971398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
    Wang X; Campoli M; Ko E; Luo W; Ferrone S
    J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering antibodies by yeast display.
    Boder ET; Raeeszadeh-Sarmazdeh M; Price JV
    Arch Biochem Biophys; 2012 Oct; 526(2):99-106. PubMed ID: 22450168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rapid discovery of engineered antibodies.
    Wang M; He M
    IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
    Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
    J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of monoclonal antibody fragments from phage display libraries.
    Arbabi-Ghahroudi M; Tanha J; MacKenzie R
    Methods Mol Biol; 2009; 502():341-64. PubMed ID: 19082566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions.
    Pindrus M; Shire SJ; Kelley RF; Demeule B; Wong R; Xu Y; Yadav S
    Mol Pharm; 2015 Nov; 12(11):3896-907. PubMed ID: 26407030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic antibody production technologies: molecules, applications, expression and purification.
    Humphreys DP; Glover DJ
    Curr Opin Drug Discov Devel; 2001 Mar; 4(2):172-85. PubMed ID: 11378956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.